ctDNA has suggested a novel therapeutic rechallenge strategy for CRC based on evidence that resistance mechanisms to anti-EGFR therapy extinguish over time off of that therapy (Misale et al., 2014; Parseghian et al., 2019; Sartore-Bianchi et al., 2021). Here, EGFR is linked to colorectal carcinoma.